Carmustine Implants in Treating Patients With Brain Metastases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2002-04-30

Study Completion Date

2003-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of implanted carmustine wafers in treating patients who have brain metastases and who are undergoing surgery to remove the tumor.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma

NCT00003467

Brain and Central Nervous System Tumors

COMPLETED PHASE2

Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas

NCT00003463

Brain and Central Nervous System Tumors

COMPLETED PHASE1

Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma

NCT00003876

Brain and Central Nervous System Tumors

COMPLETED PHASE1

Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm

NCT00009854

Brain and Central Nervous System Tumors Metastatic Cancer

UNKNOWN PHASE1/PHASE2

Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme

NCT00984438

Glioblastoma Multiforme

WITHDRAWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Determine the local recurrence rate in patients with supratentorial metastatic brain tumors undergoing surgical resection treated with polifeprosan 20 with carmustine implant (Gliadel wafers).
* Determine the incidence and time to recurrence at distant sites within the CNS in these patients after this treatment.
* Determine the median, 6-month, 1-year, and 2-year survival of these patients on this regimen.
* Determine the incidence and severity of cognitive function loss of these patients on this regimen.
* Determine the incidence and severity of CNS and systemic toxic effects of these patients on this regimen.

OUTLINE: Patients receive up to 8 polifeprosan 20 with carmustine implants (Gliadel wafers) implanted in the resected tumor cavity.

Patients are followed on day 7 or day of discharge, at 1 month, 3 months, every 3 months for 21 months, and then for survival.

PROJECTED ACCRUAL: A total of 90 patients will be accrued for this study within 30 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Cancer Unspecified Adult Solid Tumor, Protocol Specific

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

polifeprosan 20 with carmustine implant

Intervention Type DRUG

conventional surgery

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Supratentorial brain metastases for which surgery is recommended

* Solitary, unilateral, intracranial mass consistent with metastasis on MRI scan OR
* Two brain lesions consistent with metastases on MRI scan
* Lesions must be accessible through a single craniotomy
* Metastatic lesions clearly distinct from tumor bed of any benign lesions
* Intraoperative frozen section diagnosis of metastatic tumor from CNS lesion
* No prior malignant intracranial neoplasm
* No lesion(s) in the brainstem
* No open communication of the resection cavity with the ventricle following resection

PATIENT CHARACTERISTICS:

Age

* 18 and over

Performance status

* Karnofsky 60-100%

Life expectancy

* At least 3 months

Hematopoietic

* No concurrent hematologic disorders

Hepatic

* No concurrent hepatic disease

Renal

* No concurrent renal disease

Cardiovascular

* No concurrent cardiac disease

Pulmonary

* No concurrent pulmonary disorders

Other

* Not pregnant or nursing
* Fertile patients must use effective contraception
* Mini mental score at least 15
* No known hypersensitivity to carmustine or Gliadel wafers
* No other serious concurrent medical illness or infection

PRIOR CONCURRENT THERAPY:

Biologic therapy

* Not specified

Chemotherapy

* Not specified

Endocrine therapy

* Not specified

Radiotherapy

* No prior cranial irradiation

Surgery

* See Disease Characteristics
* No prior surgery involving brain metastases or primary brain tumor(s) (except for benign intracranial lesions such as pituitary adenoma, meningioma, or schwannoma)

Other

* Concurrent systemic therapy allowed

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No